Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of “Moderate Buy” by Brokerages

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $44.00.

A number of analysts recently weighed in on ASMB shares. Guggenheim reissued a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a research note on Thursday, May 28th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Assembly Biosciences in a report on Monday, May 4th. Wall Street Zen lowered Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Mizuho set a $45.00 price objective on Assembly Biosciences and gave the company an “outperform” rating in a research note on Monday, June 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp bought a new position in shares of Assembly Biosciences during the second quarter valued at $660,000. Bank of America Corp DE boosted its stake in shares of Assembly Biosciences by 113.3% in the 1st quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock valued at $303,000 after purchasing an additional 5,792 shares in the last quarter. Stempoint Capital LP grew its holdings in shares of Assembly Biosciences by 18.3% in the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock worth $5,146,000 after purchasing an additional 28,707 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Assembly Biosciences by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock worth $23,479,000 after purchasing an additional 11,384 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Assembly Biosciences by 69.4% during the 1st quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 6,411 shares in the last quarter. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Price Performance

ASMB opened at $32.95 on Friday. The company has a market capitalization of $523.58 million, a P/E ratio of 32.30 and a beta of 1.10. The firm’s fifty day moving average price is $26.09 and its two-hundred day moving average price is $27.38. Assembly Biosciences has a fifty-two week low of $20.23 and a fifty-two week high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52. The company had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. On average, equities research analysts expect that Assembly Biosciences will post 1.9 EPS for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.